Chengdu Clover Biopharma received $38.9 million from CEPI to complete the development of its COVID-19 vaccine through market approval. With the latest funds, CEPI, the Coalition for Epidemic Preparedness Innovations, has earmarked almost $400 million to develop SCB-2019 (CpG 1018/Alum), one of CEPI’s largest investments in any COVID-19 vaccine company so far. Once the vaccine is approved, Clover will supply up to 414 million doses to the COVAX Facility for global distribution. More details.... Stock Symbol: (HK: 2197) Share this with colleagues: // //